Annovis Bio, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $25.2M | $20.0M | $38.8M | $16.5M | $8.5M | $3.1M |
| SG&A Expense | $4.5M | $6.7M | $6.2M | $9.0M | $6.1M | $3.6M |
| Operating Income | $-29.7M | $-26.7M | $-45.0M | $-25.5M | $-14.5M | $-6.6M |
| Operating Margin | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | — | $-56.2M | $-25.3M | $-14.5M | $-5.5M |
| Income Tax Expense | $0 | — | — | — | — | — |
| Net Income | $-28.9M | $-24.6M | $-56.2M | $-25.3M | $-14.5M | $-5.5M |
| Net Margin | — | — | — | — | — | — |
| EPS (Basic) | $-1.40 | $-2.02 | $-6.23 | $-3.10 | $-1.90 | $-0.87 |
| EPS (Diluted) | $-1.40 | $-2.31 | $-6.23 | $-3.10 | $-1.90 | $-0.87 |
| Shares Outstanding (Basic) | 20.6M | 12.2M | 9.0M | 8.2M | 7.6M | 6.3M |
| Shares Outstanding (Diluted) | 20.6M | 12.2M | 9.0M | 8.2M | 7.6M | 6.3M |
| Dividends Per Share | — | — | — | — | — | — |